Trial Profile
Therapeutic Efficacy Comparison of a Six-month Treatment by Itraconazole and Nebulised Ambisome Versus Treatment by Itraconazole Alone in Non- or Mildly- Immunocompromised Patients With Chronic Pulmonary Aspergillosis: a Prospective, Randomized, Single Blind Study, (Single Aspergilloma Excluded)
Status:
Recruiting
Phase of Trial:
Phase III
Latest Information Update: 08 Dec 2023
Price :
$35
*
At a glance
- Drugs Amphotericin B liposomal (Primary) ; Itraconazole (Primary) ; Posaconazole; Voriconazole
- Indications Aspergillosis; Invasive bronchopulmonary aspergillosis
- Focus Therapeutic Use
- Acronyms CPAAARI
- 16 Mar 2023 Planned End Date changed from 1 Jul 2023 to 1 Dec 2029.
- 16 Mar 2023 Planned primary completion date changed from 1 Jun 2023 to 1 Jun 2027.
- 09 Feb 2022 Planned primary completion date changed from 1 Jun 2021 to 1 Jun 2023.